Repirinast

Repirinast (MY-5116) is an orally active anti-allergic agent. Repirinast inhibits histamine release. Repirinast can be used in the research of bronchial asthma[1][2][3].

Product Specifications

CAS Number

[73080-51-0]

Product Name Alternative

MY-5116

UNSPSC

12352005

Target

Histamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/repirinast.html

Purity

95.30

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C(O1)=CC(C2=C1C3=C(NC2=O)C(C)=C(C)C=C3)=O)OCCC(C)C

Molecular Formula

C20H21NO5

Molecular Weight

355.38

References & Citations

[1]N Yamada, et al. Repirinast inhibits antigen-induced early and late pulmonary responses and airway hyperresponsiveness in guinea pigs. Int Arch Allergy Immunol. 1993;100 (4) :367-72. |[2]Takahashi K. Effects of MY-5116 on experimental asthma in rats and guinea pigs. Arerugi. 1986 Oct; 35 (10) : 1037-46. |[3]M Takei, et al. Inhibition of histamine release from rat peritoneal mast cells by MY-1250, an active metabolite of Repirinast (MY-5116) . Int Arch Allergy Appl Immunol. 1990;93 (2-3) :237-41.